Incyte raises 2026 sales forecast as third-quarter revenue reaches $1.51 billion
The company lost $3.60 a share, $0.33 better than analysts expected.
Published
Chart: INCY, one-minute prices, three sessions
Incyte raised its full-year 2026 net sales forecast to $5,210 million to $5,300 million. Its previous range was $5,130 million to $5,260 million. Third-quarter revenue came in at $1.51 billion, against $1.50 billion expected.
Chief executive Bill Meury said sales grew strongly in both the U.S. and abroad. He said that gives the company a durable core business beyond Jakafi.
The forecast for Opzelura rose to $1,100 million to $1,120 million, from $1,050 million to $1,100 million. The forecast for the hematology and oncology products rose to $890 million to $910 million, from $860 million to $890 million.
Jakafi's core patents expire in mid and late 2028. Opzelura is the product Incyte is counting on to fill that gap, so the raised range matters. One analysis of the second quarter attributed much of that quarter's forecast increase to a $246 million benefit from reversing accounting provisions set aside earlier for Opzelura. The company's release does not separate that effect from underlying demand. If the third-quarter Opzelura change reflects prescriptions rather than accounting, it would support the company's case that its core business is broadening beyond Jakafi.
© Raydn · raydn.us